Boston Consulting Group (BCG), one of the four major consulting companies in the world, recently released an industry analysis report, entitled Direction for the Development of the Drug Circulation Industry in China. The report noted that the drug circulation industry in China at present reveals three most important characteristics, i.e., a great number of enterprises, relatively low concentration and a dire need for optimization of industry structure; leading players active in expanding ability for comprehensive services with professional competencies yet to be improved; and constantly emerging new business formats and business models. The report summarized alignment of the drug circulation industry to international trends, the direction for its future development in China and challenges; BAHEAL Pharmaceutical Group (BPG), as a representative of innovative companies in China’s drug circulation industry, provides up- and downstream total solutions for the entire industrial chain and fully understands the future directions of the industry.

BAHEAL Pharmaceutical Group (BPG) once again become the focus of Qingdao Daily today, with an article entitled “BAHEAL PHARMA: Devoted to Improving Health through Science and Technology” published in the special column of “Conversion from Old to New Kinetic Energies in Qingdao and Highlights across Top 10 Industries” on the second page of the daily newspaper.

BAHEAL Pharmaceutical, a high-end manufacturer of generics in China, of the BAHEAL Pharmaceutical Group, has five generics projects available that have been granted the support for initiation of special projects on the innovation and manufacturing of major new drugs under the 13th Five-year Plan of the state and has become one of the globalized generics producers in China, which also implies that BAHEAL Pharmaceutical has become a leading player across the industry in terms of the capacity in innovation and manufacturing of high-end generics and that the pharmaceutical accompanies in China are also embracing a new epoch that focuses on technology as a core competitiveness.

May 5 witnessed the founding of the Chinese Intelligent Medicine Association of Chinese Medical Doctors Association (CMDA) in Beijing, with presence of LIU Wenxian, Deputy Director-general of the Planning and Information Department under National Health Commission of China; President ZHANG Yanling of Chinese Medical Doctors Association; YOU Zheng, Vice President and member of the Standing CPC Committee at Tsinghua University; Professor Lawrence, Vice President of Duke University in the United States; DONG Jiahong, an academician with the Chinese Academy of Engineering; and BPG Chairman FU Gang, among others.